Cargando…
Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors
BACKGROUND: The optimal treatment for adrenal metastases from hepatocellular carcinoma (HCC) has not been established. This study analyzed the effects of radiation therapy (RT) for such metastases and identified clinical features and predictors of survival in these patients. METHODS: We retrospectiv...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289365/ https://www.ncbi.nlm.nih.gov/pubmed/25421498 http://dx.doi.org/10.1186/1471-2407-14-878 |
_version_ | 1782352103293845504 |
---|---|
author | Zhou, Le-Yuan Zeng, Zhao-Chong Fan, Jia Chen, Bing Rao, Sheng-xiang He, Jian Yang, Ping Hou, Jia-zhou Wu, Zhi-feng Zhang, Jian-ying Hu, Yong |
author_facet | Zhou, Le-Yuan Zeng, Zhao-Chong Fan, Jia Chen, Bing Rao, Sheng-xiang He, Jian Yang, Ping Hou, Jia-zhou Wu, Zhi-feng Zhang, Jian-ying Hu, Yong |
author_sort | Zhou, Le-Yuan |
collection | PubMed |
description | BACKGROUND: The optimal treatment for adrenal metastases from hepatocellular carcinoma (HCC) has not been established. This study analyzed the effects of radiation therapy (RT) for such metastases and identified clinical features and predictors of survival in these patients. METHODS: We retrospectively investigated 55 patients with adrenal metastasis from HCC who had been treated with RT. Radiation doses to the adrenal lesions ranged from 26 to 60 Gy, while the intrahepatic lesions were treated by surgical resection, transarterial chemoembolization (TACE), liver transplantation, and/or RT. RT was conducted to adrenal lesions after their intrahepatic lesions were controlled more than 2 months. The parameters studied included survival rates and tumor responses to RT. The Kaplan-Meier method was used to evaluate survival rate and the Cox regression model was used to identify potential predictors of outcome. RESULTS: The patients treated by RT had adrenal metastasis on the right side (41), the left (6), or on both sides (8). In all 55 patients, the median survival duration was 13.6 months and there was 100% pain relief after completion of RT. Adverse effects were mild to moderate. Unfavorable pretreatment predictors determined by univariate analysis were associated with multiple intrahepatic foci, metastases to additional organs, high γ-glutamyltransferase and alpha-fetoprotein levels, liver function of Child-Pugh classification B and uncontrolled primary HCC. By multivariate analysis, unfavorable predictors were multiple intrahepatic foci, metastases to additional organs and uncontrolled primary HCC. CONCLUSIONS: Radiotherapy as treatment for adrenal metastases in HCC is a good palliative therapy that is associated with reasonable safety. It appears reasonable that such patients should be considered to be treated with radiotherapy. Multiple intrahepatic foci, metastases to additional organs and uncontrolled primary HCC were unfavorable predictors. |
format | Online Article Text |
id | pubmed-4289365 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42893652015-01-11 Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors Zhou, Le-Yuan Zeng, Zhao-Chong Fan, Jia Chen, Bing Rao, Sheng-xiang He, Jian Yang, Ping Hou, Jia-zhou Wu, Zhi-feng Zhang, Jian-ying Hu, Yong BMC Cancer Research Article BACKGROUND: The optimal treatment for adrenal metastases from hepatocellular carcinoma (HCC) has not been established. This study analyzed the effects of radiation therapy (RT) for such metastases and identified clinical features and predictors of survival in these patients. METHODS: We retrospectively investigated 55 patients with adrenal metastasis from HCC who had been treated with RT. Radiation doses to the adrenal lesions ranged from 26 to 60 Gy, while the intrahepatic lesions were treated by surgical resection, transarterial chemoembolization (TACE), liver transplantation, and/or RT. RT was conducted to adrenal lesions after their intrahepatic lesions were controlled more than 2 months. The parameters studied included survival rates and tumor responses to RT. The Kaplan-Meier method was used to evaluate survival rate and the Cox regression model was used to identify potential predictors of outcome. RESULTS: The patients treated by RT had adrenal metastasis on the right side (41), the left (6), or on both sides (8). In all 55 patients, the median survival duration was 13.6 months and there was 100% pain relief after completion of RT. Adverse effects were mild to moderate. Unfavorable pretreatment predictors determined by univariate analysis were associated with multiple intrahepatic foci, metastases to additional organs, high γ-glutamyltransferase and alpha-fetoprotein levels, liver function of Child-Pugh classification B and uncontrolled primary HCC. By multivariate analysis, unfavorable predictors were multiple intrahepatic foci, metastases to additional organs and uncontrolled primary HCC. CONCLUSIONS: Radiotherapy as treatment for adrenal metastases in HCC is a good palliative therapy that is associated with reasonable safety. It appears reasonable that such patients should be considered to be treated with radiotherapy. Multiple intrahepatic foci, metastases to additional organs and uncontrolled primary HCC were unfavorable predictors. BioMed Central 2014-11-25 /pmc/articles/PMC4289365/ /pubmed/25421498 http://dx.doi.org/10.1186/1471-2407-14-878 Text en © Zhou et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Zhou, Le-Yuan Zeng, Zhao-Chong Fan, Jia Chen, Bing Rao, Sheng-xiang He, Jian Yang, Ping Hou, Jia-zhou Wu, Zhi-feng Zhang, Jian-ying Hu, Yong Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors |
title | Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors |
title_full | Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors |
title_fullStr | Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors |
title_full_unstemmed | Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors |
title_short | Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors |
title_sort | radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289365/ https://www.ncbi.nlm.nih.gov/pubmed/25421498 http://dx.doi.org/10.1186/1471-2407-14-878 |
work_keys_str_mv | AT zhouleyuan radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors AT zengzhaochong radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors AT fanjia radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors AT chenbing radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors AT raoshengxiang radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors AT hejian radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors AT yangping radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors AT houjiazhou radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors AT wuzhifeng radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors AT zhangjianying radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors AT huyong radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors |